Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1995 3
1996 1
1997 2
1998 17
1999 49
2000 61
2001 165
2002 295
2003 356
2004 495
2005 599
2006 610
2007 725
2008 710
2009 684
2010 716
2011 672
2012 720
2013 727
2014 729
2015 672
2016 722
2017 684
2018 629
2019 289
2020 12
Text availability
Article attribute
Article type
Publication date

Search Results

9,989 results
Results by year
Filters applied: . Clear all
Page 1
Psoriasis
Greb JE, et al. Nat Rev Dis Primers 2016 - Review. PMID 27883001
Infliximab-Related Infusion Reactions: Systematic Review.
Lichtenstein L, et al. J Crohns Colitis 2015 - Review. PMID 26092578 Free PMC article.
METHODS: We conducted extensive search of electronic databases of MEDLINE [PubMed] for reports that communicate various aspects of infusion reactions to infliximab in IBD patients. ...CONCLUSIONS: There is still paucity of systematic and controlled data on the risk, prevention, and management of infusion reactions to infliximab. ...
METHODS: We conducted extensive search of electronic databases of MEDLINE [PubMed] for reports that communicate various aspects of infusion …
Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series.
Gelfand JM, et al. Neurology 2017. PMID 29030454 Free PMC article.
OBJECTIVE: To describe clinical and imaging responses in neurosarcoidosis to infliximab, a monoclonal antibody against tumor necrosis factor-α. ...RESULTS: Of 66 patients with CNS sarcoidosis (27 definite, 39 probable) treated with infliximab for a median of 1.5 years, the mean age was 47.5 years at infliximab initiation (SD 11.7, range 24-71 years); 56.1% were female; 62.1% were white, 37.0% African American, and 3% Hispanic. ...
OBJECTIVE: To describe clinical and imaging responses in neurosarcoidosis to infliximab, a monoclonal antibody against tumor necrosis …
Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease.
Hemperly A and Vande Casteele N. Clin Pharmacokinet 2018 - Review. PMID 29330783
The administration of infliximab is weight-based and the drug is administered intravenously. The volume of distribution of infliximab is low and at steady state ranges from 4.5 to 6 L. ...Median infliximab half-life is approximately 14 days. Infliximab concentration-time data in patients with CD and UC have been shown to be highly variable within an individual patient over time and between individuals by multiple population pharmacokinetic models. ...
The administration of infliximab is weight-based and the drug is administered intravenously. The volume of distribution of inflixi
SB2: An Infliximab Biosimilar.
Lamb YN, et al. BioDrugs 2017 - Review. PMID 28803431
SB2 is a biosimilar of the reference anti-TNF-α antibody infliximab. In May 2015, it was approved in the EU for use in all indications for which reference infliximab is approved, including rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriatic arthritis and psoriasis. ...Switching from reference infliximab to SB2 did not impact clinical efficacy, safety or immunogenicity. The role of reference infliximab in the management of autoimmune inflammatory conditions is well established, and SB2 provides an effective biosimilar alternative for patients requiring infliximab therapy....
SB2 is a biosimilar of the reference anti-TNF-α antibody infliximab. In May 2015, it was approved in the EU for use in all indication …
Primary and secondary nonresponse to infliximab: mechanisms and countermeasures.
Wong U and Cross RK. Expert Opin Drug Metab Toxicol 2017 - Review. PMID 28876147
Primary and secondary non-response to infliximab are common in patients with inflammatory bowel disease and remain a management challenge in clinical practice. ...An algorithm for evaluation and management of non-response to infliximab is provided. Preventative measures are also discussed. ...
Primary and secondary non-response to infliximab are common in patients with inflammatory bowel disease and remain a management chall …
PF-06438179/GP1111: An Infliximab Biosimilar.
Al-Salama ZT. BioDrugs 2018 - Review. PMID 30284704 Free PMC article.
The tolerability, immunogenicity and safety profiles of GP1111 were similar to those of reference infliximab, and switching from reference infliximab to GP1111 had no impact on safety, efficacy or immunogenicity. The role of reference infliximab in the management of autoimmune inflammatory conditions is well established and GP1111 provides an effective biosimilar alternative for patients requiring infliximab therapy....
The tolerability, immunogenicity and safety profiles of GP1111 were similar to those of reference infliximab, and switching from refe …
Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial.
Mori M, et al. Sci Rep 2018 - Clinical Trial. PMID 29386515 Free PMC article.
Defervescence rate within 48 h was greater with infliximab (76.7%) than VGIH (37.0%) (p = 0.023), and defervescence was achieved earlier with infliximab (p = 0.0072). ...Adverse events occurred in 15 (93.8%) and 15 (100.0%) patients in the infliximab and VGIH groups, respectively. No serious adverse events in the infliximab group and one in the VGIH group were observed. ...
Defervescence rate within 48 h was greater with infliximab (76.7%) than VGIH (37.0%) (p = 0.023), and defervescence was achieved earl …
[Infliximab].
Goujon C, et al. Ann Dermatol Venereol 2019. PMID 31230775 French.
Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.
Ye BD, et al. Lancet 2019 - Clinical Trial. PMID 30929895
Patients were randomly assigned (1:1:1:1) to receive CT-P13 then CT-P13, CT-P13 then infliximab, infliximab then infliximab, or infliximab then CT-P13, with switching occurring at week 30. ...FINDINGS: Between Aug 20, 2014, and Feb 15, 2017, 308 patients were assessed for eligibility, and 220 patients were enrolled: 111 were randomly assigned to initiate CT-P13 (56 to the CT-P13-CT-P13 group and 55 to the CT-P13-infliximab group) and 109 to initiate infliximab (54 to the infliximab-infliximab group and 55 to the infliximab-CT-P13 group). ...
Patients were randomly assigned (1:1:1:1) to receive CT-P13 then CT-P13, CT-P13 then infliximab, infliximab then infliximab
9,989 results
Jump to page
Feedback